ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: New San Antonio Center Wins Core Grants; ASCO forming A Technology Assessment Committee

July 19, 1991

Industry Groups Lobby for Lower Standards for FDA Approval

November 18, 2011

Chaos In Congress Killed $20 Million Increase For NCI

December 19, 1980

NCI To Voluntarily Spends $196 Million On Breast Cancer; Will Require Reallocation

November 13, 1992

Stand Up To Cancer Selects Five Groups For “Dream Team” Grants Totaling $73.6M.

May 29, 2009

New Tests Rule Out Theory On Polio Vaccine-AIDS Link.

October 6, 2000